Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

In the past, patients diagnosed with rare cancer types often faced a bleak prognosis due to limited treatment options. Today, the story is different, as advances in precision medicine and the development of new, targeted therapies continue to permeate the oncology space.
In 2012, August 1 was declared World Lung Cancer Day—11 years later, its significance is as important as ever.
Texas Society of Medical Oncology Educational Award for Allied Health Professionals Submission Deadline: Friday, September 8, 2023 OVERVIEW The Nevada Oncology Society (NOS) is committed to focusing on the future of cancer care In Nevada by supporting the professional development of Advanced Practice Providers, Pharmacists and Registered Nurses in the …
Caregivers experience higher levels of financial, emotional, and physical health difficulties than non-caregivers and are more likely to suffer from depressive symptoms and mental health problems. The Caregivers Clinic at Memorial Sloan Kettering Cancer Center is the first of its kind and provides comprehensive psychosocial care to family members and friends of patients who experience significant distress …
Targeted Oncology’s Register Today targetedonc.com/events Seating is limited, and registration will close when capacity is reached. Reserve your seat today! Therapeutic Sequencing for Metastatic Breast Cancer MODERATOR TO BE ANNOUNCED Targeted Therapies for Metastatic NSCLC MODERATED BY Devika Das, MD, MSHQS Stay informed on the latest research data in an informal, case-based …
SCOS 2023 Annual Conference August 4th - 5th, 2023 Wild Dunes Resort, Isle of Palms, South Carolina Attendee Roster First Name Last Name Title Account Name Kevin Brewer Account Executive AbbVie Inc. Felicia Hand RN, MSN, OCN, MSL AbbVie Inc. Leiza McLeod Account Executive AbbVie Inc. Mickey Register Medical Science Liaison AbbVie Inc. Nahir Rivera Medical Science Liaison AbbVie …
IOS FELLOWS & CAREER PROFESSIONALS KEYNOTE DINNER REVIEW OF ASCO® 2023IOS Thursday, August 24, 2023 5:30 pm – 8:30 pm cdt SCAN HERE OR VISIT HTTPS://BIT.LY/IOS-FELLOWS FOR COMPLIMENTARY REGISTRATION! Join us the evening before the IOS 2023 Review of ASCO® for the IOS Fellows & Career Professionals Keynote Dinner. This complimentary event is crafted for fellows and seasoned experts …
Learn how the creation of the first advanced practice radiation therapist (APRT) role in the United States established a new model of inpatient care, elevating the radiation therapy skill set and allowing for intervention at key points along the radiation oncology care pathway.
By implementing e-consults for patients experiencing endocrine immune-related adverse events, Duke Cancer Institute improved patient access and reduced healthcare utilization.
ACCC is working with multidisciplinary care teams to assess the impact of SDOH on equitable access to cancer care and clinical trials among minority populations.
In this episode, hear about the fully remote TRACK (Target Rare Cancer Knowledge) clinical trial and its unique approach to providing access to biomarker testing for patients in community care settings by leveraging technology.
July 22, 2023
Best of ASCO®, an Official Annual Meeting Review of the American Society of Clinical Oncology® (ASCO®), is a two-day program designed to provide the latest science and education from the world’s premier oncology event, the ASCO® Annual Meeting. The abstracts selected for presentation and discussion reflect the foremost research and strategies in oncology that will impact clinical practice and patient …
July 20, 2023
In this final webinar, hear from our experts Jordan Karwedsky, Financial Counselor, Green Bay Oncology, Wendi Waugh, BS, RT(R)(T), CMD, CRT, Administrative Director of SOMC Cancer Services & Ambulatory Infusion, Southern Ohio Medical Center, and Dr. Michael R. Gieske, Director of Lung Cancer Screening. Join us as we discuss prior authorization challenges in biomarker testing, importance of providing …
SCOS ONCOLOGY DRUG NEWSLETTER FDA APPROVALS Flotufolastat F 18 injection (Posluma) The FDA has granted approval for the flotufolastat F 18 injection (Posluma; formerly 18F-rhPSMA-7.3) for PET of prostate-specific membrane antigen–positive lesions in patients with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or in those with suspected recurrence …
TxSCO Monthly Update 2023-07-13 July 13, 2023 TxSCO Update Overview: Notable Updates 2 Federal • EOM participants announced • Site neutral payments • 340B Proposed Rule • Appendix • PBM reforms • Biden Administration’s “Persistent Poverty Initiative” to Combat Cancer Inequities • Oncology drug shortages • EOM: additional context State • Special …
TACOS ONCOLOGY DRUG NEWSLETTER FDA APPROVALS Flotufolastat F 18 injection (Posluma) The FDA has granted approval for the flotufolastat F 18 injection (Posluma; formerly 18F-rhPSMA-7.3) for PET of prostate-specific membrane antigen–positive lesions in patients with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or in those with suspected recurrence …
TxSCO ONCOLOGY DRUG NEWSLETTER FDA APPROVALS Flotufolastat F 18 injection (Posluma) The FDA has granted approval for the flotufolastat F 18 injection (Posluma; formerly 18F-rhPSMA-7.3) for PET of prostate-specific membrane antigen–positive lesions in patients with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or in those with suspected recurrence …
NCOA ONCOLOGY DRUG NEWSLETTER FDA APPROVALS Flotufolastat F 18 injection (Posluma) The FDA has granted approval for the flotufolastat F 18 injection (Posluma; formerly 18F-rhPSMA-7.3) for PET of prostate-specific membrane antigen–positive lesions in patients with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or in those with suspected recurrence …